A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

Inclusion Criteria:

• Participants must have a confirmed diagnosis of epithelial ovarian, fallopian tube,and primary peritoneal cancer (EOC) with high FRα expression.

• Participant's tumor must be FRα positive (FRα high) as defined by either the VENTANAFOLR1 (FOLR-2.1) IUO Assay, or the VENTANA FOLR1 ( FOLR1-2.1) RxDx Assay (hereaftercollectively termed VENTANA FOLR1 Assay) (≥ 75% cells exhibit ≥ 2+ membrane stainingintensity).

• Participants with known breast cancer susceptibility gene (BRCA) mutations (tumor orgermline) must have received poly (ADP-ribose) polymerase inhibitors (PARPi).

• Participants must have completed prior therapy within the specified times below:

1. Systemic antineoplastic therapy ≥ 5 half-lives or 4 weeks (whichever isshorter) before first dose of MIRV;

2. Focal radiation completed ≥ 2 weeks before the first dose of MIRV.

• Participants must have stabilized or recovered (Grade 1 or baseline) from all priortherapy-related toxicities (except alopecia).

• Women of childbearing potential (WOCBP) must agree to use highly effectivecontraceptive method(s) while on MIRV and for ≥ 7 months after the last dose; andmust have a negative pregnancy test ≤ 4 days before the first dose of MIRV.

Exclusion Criteria:

• Participants with borderline ovarian tumor or non-epithelial histology or mixedhistology including borderline or non-epithelial histology will be excluded.

• PROC participants with primary platinum-refractory disease, defined as disease thatdid not respond to (complete response [CR] or partial response [PR]) or progressedwithin ≤ 3 months of the last dose of first line platinum-containing chemotherapy.

• Participants with > Grade 1 peripheral neuropathy per National CancerInstitute-Common Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAEv5.0).

• Participants with significant active or chronic corneal disorders (for example,corneal dystrophies, degenerations, limbal stem cell deficiency), history of cornealtransplantation, significant ocular inflammatory conditions (for example, active orrecurrent uveitis), or other active ocular conditions requiring ongoingtreatment/monitoring, such as uncontrolled glaucoma, active diabetic retinopathywith macular edema, macular degeneration requiring treatment ≤ 90 days before firstdose, presence of papilledema, best corrected visual acuity (BCVA) worse than 20/70in either eye, or monocular vision.

• Participants receiving corticosteroid or vasoconstricting eyedrops at baseline orwithin 5 weeks of Cycle 1 Day 1.

• Participants who received prior treatment with MIRV or other FRα-targeting agents.Note: Other protocol-defined inclusion and exclusion criteria may apply.